TR201807023T4 - Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri. - Google Patents

Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri. Download PDF

Info

Publication number: TR201807023T4
Authority: TR; Turkey
Prior art keywords: compound; methyl; amino; phenyl; compounds
Prior art date: 2012-05-15

Application number

TR2018/07023T

Other languages

English (en)

Turkish (tr)

Inventor

Kay Dodd Stephanie

Furet Pascal

Martin Grotzfeld Robert

Brynley Jones Darryl

Manley Paul

Marzinzik Andreas

Francois Andre Pelle Xavier

Salem Bahaa

Schoepfer Joseph

Jahnke Wolfgang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-15

Filing date

2013-05-09

Publication date

2018-06-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201807023(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-05-09 Application filed by Novartis Ag filed Critical Novartis Ag

2018-06-21 Publication of TR201807023T4 publication Critical patent/TR201807023T4/tr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Hydrogenated Pyridines (AREA)

TR2018/07023T 2012-05-15 2013-05-09 Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri. TR201807023T4 (tr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261647174P	2012-05-15	2012-05-15
US201361790967P	2013-03-15	2013-03-15

Publications (1)

Publication Number	Publication Date
TR201807023T4 true TR201807023T4 (tr)	2018-06-21

Family

ID=48670630

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TR2018/07023T TR201807023T4 (tr)	2012-05-15	2013-05-09	Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri.

Country Status (50)

Country	Link
US (2)	US8829195B2 (fr)
EP (1)	EP2861579B9 (fr)
JP (1)	JP6078639B2 (fr)
KR (1)	KR102091893B1 (fr)
CN (1)	CN104302638B (fr)
AP (1)	AP3613A (fr)
AR (1)	AR091063A1 (fr)
AU (1)	AU2013261127B2 (fr)
BR (1)	BR112014026383B1 (fr)
CA (1)	CA2868958C (fr)
CL (1)	CL2014002757A1 (fr)
CO (1)	CO7131380A2 (fr)
CR (1)	CR20140519A (fr)
CU (1)	CU24265B1 (fr)
CY (2)	CY1120235T1 (fr)
DK (1)	DK2861579T5 (fr)
DO (1)	DOP2014000256A (fr)
EA (1)	EA024391B1 (fr)
ES (1)	ES2670601T3 (fr)
FR (1)	FR22C1053I2 (fr)
GE (1)	GEP201606532B (fr)
GT (1)	GT201400253A (fr)
HR (1)	HRP20180695T1 (fr)
HU (2)	HUE039138T2 (fr)
IL (1)	IL235566A (fr)
JO (1)	JO3453B1 (fr)
LT (2)	LT2861579T (fr)
LU (1)	LUC00287I2 (fr)
MA (1)	MA37519B1 (fr)
ME (1)	ME03095B (fr)
MX (1)	MX359014B (fr)
MY (1)	MY169377A (fr)
NL (1)	NL301201I2 (fr)
NO (1)	NO2022043I1 (fr)
NZ (1)	NZ701626A (fr)
PE (3)	PE20210667A1 (fr)
PH (1)	PH12014502531B1 (fr)
PL (1)	PL2861579T3 (fr)
PT (1)	PT2861579T (fr)
RS (1)	RS57177B1 (fr)
SG (1)	SG11201407152XA (fr)
SI (1)	SI2861579T1 (fr)
SV (1)	SV2014004850A (fr)
TN (1)	TN2014000427A1 (fr)
TR (1)	TR201807023T4 (fr)
TW (1)	TWI560183B (fr)
UA (1)	UA113208C2 (fr)
UY (1)	UY34811A (fr)
WO (1)	WO2013171639A1 (fr)
ZA (1)	ZA201407065B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT2841437T (lt)	2012-04-26	2017-09-11	Bristol-Myers Squibb Company	Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuotų receptorių 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
PT2861579T (pt) *	2012-05-15	2018-04-27	Novartis Ag	Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
ES2670667T3 (es) *	2012-05-15	2018-05-31	Novartis Ag	Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1
WO2013171641A1 (fr)	2012-05-15	2013-11-21	Novartis Ag	Composés et compositions pour l'inhibition de l'activité abl1, abl2 et bcr-abl1
KR20150008406A (ko) *	2012-05-15	2015-01-22	노파르티스 아게	Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
JP6437452B2 (ja)	2013-01-14	2018-12-12	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
RS60244B1 (sr)	2013-01-15	2020-06-30	Incyte Holdings Corp	Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
CN105658653A (zh)	2013-08-23	2016-06-08	因赛特公司	可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
CN106414402A (zh) *	2013-11-01	2017-02-15	宇部兴产株式会社	丙烯酰(氧基或氨基)五氟硫烷基苯化合物、其药学可接受的盐及其前药
SG10201900002QA (en)	2014-01-24	2019-02-27	Dana Farber Cancer Institue Inc	Antibody molecules to pd-1 and uses thereof
EP3099717B1 (fr)	2014-01-31	2019-03-27	Novartis AG	Molécules d'anticorps anti-tim-3 et leurs utilisations
JP2017512183A (ja)	2014-02-13	2017-05-18	リガンド・ファーマシューティカルズ・インコーポレイテッド	プロドラッグ化合物およびそれらの使用
US20150259420A1 (en)	2014-03-14	2015-09-17	Novartis Ag	Antibody molecules to lag-3 and uses thereof
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (fr)	2014-07-14	2016-01-21	Incyte Corporation	Composés carboxamide hétéroaromatiques bicycliques utiles en tant qu'inhibiteurs de kinases pim
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh)	2014-10-14	2021-01-21	瑞士商諾華公司	針對ｐｄ－ｌ１之抗體分子及其用途
WO2016100882A1 (fr)	2014-12-19	2016-06-23	Novartis Ag	Polythérapies
CN104478911A (zh) *	2014-12-19	2015-04-01	成都安斯利生物医药有限公司	一种制备3-三氟甲基吡咯硼酸的方法
EP3246046A4 (fr) *	2015-01-13	2018-12-05	Kyoto University	Agent pour la prévention et/ou le traitement de la sclérose latérale amyotrophique
HK1248603A1 (zh)	2015-03-10	2018-10-19	Aduro Biotech, Inc.	用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
WO2016196244A1 (fr)	2015-05-29	2016-12-08	Incyte Corporation	Composés de pyridineamine utiles en tant qu'inhibiteurs de kinase pim
US20180222982A1 (en)	2015-07-29	2018-08-09	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (fr)	2015-07-29	2021-09-15	Novartis AG	Polythérapies comprenant des molécules d'anticorps tim-3
DK3317301T3 (da)	2015-07-29	2021-06-28	Immutep Sas	Kombinationsterapier omfattende antistofmolekyler mod lag-3
TWI734699B (zh)	2015-09-09	2021-08-01	美商英塞特公司	Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en)	2015-10-02	2018-03-20	Incyte Corporation	Heterocyclic compounds useful as pim kinase inhibitors
EP3370768B9 (fr)	2015-11-03	2022-03-16	Janssen Biotech, Inc.	Anticorps se liant spécifiquement à pd-1 et leurs utilisations
WO2017106656A1 (fr)	2015-12-17	2017-06-22	Novartis Ag	Molécules d'anticorps anti-pd-1 et leurs utilisations
US9931342B2 (en)	2016-02-02	2018-04-03	Duke University	Compositions and methods for the treatment of cancer
JP2019515932A (ja) *	2016-04-29	2019-06-13	アスターバイオテックリミテッドライアビリティカンパニー	チロシンキナーゼｂｃｒ−ａｂｌ阻害剤としての新規複素環化合物
WO2018009466A1 (fr)	2016-07-05	2018-01-11	Aduro Biotech, Inc.	Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
EP3519400A1 (fr) *	2016-09-27	2019-08-07	Novartis AG	Systèmes tensioactifs pour la cristallisation de composés organiques
WO2018081372A1 (fr) *	2016-10-26	2018-05-03	The University Of Georgia Research Foundation, Inc.	Méthodes de traitement de la leucémie myéloïde
RU2768887C2 (ru) *	2017-03-15	2022-03-25	Сан Фарма Эдвансд Рисёч Компани Лимитед	Новая аморфная дисперсия (5-{ 5-[n'-(2-хлор-6-метилбензоил)гидразинокарбонил]-2-метил-фенилэтинил} -пиридин-2-ил)амида циклопропанкарбоновой кислоты
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
JPWO2018216705A1 (ja) *	2017-05-23	2020-03-26	国立大学法人京都大学	神経変性疾患の予防及び／又は治療剤
WO2018237173A1 (fr)	2017-06-22	2018-12-27	Novartis Ag	Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
AR113922A1 (es)	2017-12-08	2020-07-01	Incyte Corp	Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
RU2020126177A (ru)	2018-01-09	2022-02-10	Лиганд Фармасьютикалз, Инк.	Ацетальные соединения и их терапевтическое применение
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN119751456A (zh) *	2018-04-16	2025-04-04	C4医药公司	螺环化合物
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
KR102618168B1 (ko) *	2018-07-06	2023-12-27	일양약품주식회사	프리온 질환의 예방 또는 치료를 위한 약제학적 조성물
IL281427B2 (en)	2018-09-18	2026-01-01	Terns Inc	Compounds that inhibit tyrosine kinase activity for use in the treatment of leukemia
KR102119150B1 (ko)	2018-10-23	2020-06-04	한국원자력의학원	N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
US11236070B2 (en) *	2019-05-16	2022-02-01	Novartis Ag	Chemical process
TWI853027B (zh) *	2019-05-16	2024-08-21	瑞士商諾華公司	N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
GB201913110D0 (en) *	2019-09-11	2019-10-23	Benevolentai Bio Ltd	New compounds and methods
US20220348651A1 (en)	2019-09-18	2022-11-03	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN114728943B (zh) *	2020-01-19	2024-12-06	正大天晴药业集团股份有限公司	作为bcr-abl抑制剂的化合物
ES3057399T3 (en)	2020-01-28	2026-03-02	Tapi Czech Ind S R O	Solid state forms of asciminib and processes for the preparation thereof
US20230072528A1 (en)	2020-02-05	2023-03-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
CN111321200A (zh) *	2020-02-28	2020-06-23	广州安镝声生物医药科技有限公司	一种细胞外abl1激酶活性检测试剂盒及其应用
CN115124551B (zh) *	2021-03-24	2024-04-30	奥锐特药业(天津)有限公司	一种高纯度米哚妥林的制备方法
WO2022206937A1 (fr) *	2021-04-01	2022-10-06	苏州晶云药物科技股份有限公司	Nouvelle forme cristalline de chlorhydrate de composé nicotinamide à substitution par pyrazole et son procédé de préparation
EP4337205A1 (fr)	2021-05-11	2024-03-20	Novartis AG	Schémas posologiques
JP2024519538A (ja)	2021-05-28	2024-05-15	チアタイティエンチンファーマシューティカルグループカンパニーリミテッド	Ｂｃｒ－ａｂｌ阻害剤としての化合物
CN114149409B (zh) *	2021-11-16	2024-03-22	中国药科大学	一种具有蛋白激酶抑制活性的（杂）芳基酰胺类化合物
CN116135851B (zh) *	2021-11-17	2025-09-23	武汉众诚康健生物医药科技有限公司	一种芳香胺化合物及其应用
US20250144224A1 (en) *	2021-12-13	2025-05-08	The Regents Of The University Of California	Abl inhibitors and uses thereof
CN115109048B (zh) *	2022-08-10	2023-12-08	中国药科大学	一种(杂)芳基酰胺类化合物
WO2024100212A1 (fr)	2022-11-10	2024-05-16	Synthon B.V.	Forme cristalline du chlorhydrate d'asciminib
WO2024257116A1 (fr) *	2023-06-13	2024-12-19	Natco Pharma Limited	Nouvelles formes polymorphes d'asciminib et leurs sels pharmaceutiques
WO2025146653A1 (fr) *	2024-01-04	2025-07-10	Biophore India Pharmaceuticals Pvt. Ltd	Procédé de préparation de n-[4(chlorodifluorométhoxy)phényl]-6-[(3r)-3-hydroxy pyrrolidin-l-yl]-5-(1h-pyrazol-3-yl) pyridine-3-carboxamide et ses sels pharmaceutiquement acceptables
WO2025151311A1 (fr) *	2024-01-10	2025-07-17	Board Of Regents, The University Of Texas System	Dérivés de nicotinamide

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH445129A (fr)	1964-04-29	1967-10-15	Nestle Sa	Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en)	1966-12-16	1969-08-05	Corn Products Co	Cyclodextrin polyethers and their production
US3453257A (en)	1967-02-13	1969-07-01	Corn Products Co	Cyclodextrin with cationic properties
US3426011A (en)	1967-02-13	1969-02-04	Corn Products Co	Cyclodextrins with anionic properties
US3453259A (en)	1967-03-22	1969-07-01	Corn Products Co	Cyclodextrin polyol ethers and their oxidation products
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
DE2845997A1 (de)	1978-10-23	1980-04-30	Bayer Ag	Pflanzenwachstumsregulierende mittel, verfahren zu ihrer herstellung und ihre verwendung zur regulierung des pflanzenwachstums
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
US5093330A (en)	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
WO1989002891A1 (fr)	1987-09-23	1989-04-06	F. Hoffmann-La Roche & Co. Aktiengesellschaft	Composes heterocycliques
US5010099A (en)	1989-08-11	1991-04-23	Harbor Branch Oceanographic Institution, Inc.	Discodermolide compounds, compositions containing same and method of preparation and use
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5395855A (en)	1990-05-07	1995-03-07	Ciba-Geigy Corporation	Hydrazones
IL115849A0 (en)	1994-11-03	1996-01-31	Merz & Co Gmbh & Co	Tangential filtration preparation of liposomal drugs and liposome product thereof
EP0923583A1 (fr)	1996-08-30	1999-06-23	Novartis AG	Procede de fabrication d'epothilones, et composes intermediaires obtenus au cours de ce procede
DE69724269T2 (de)	1996-09-06	2004-06-09	Obducat Ab	Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DK1367057T3 (da)	1996-11-18	2009-01-19	Biotechnolog Forschung Gmbh	Epothiloner E og F
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
GB9721069D0 (en)	1997-10-03	1997-12-03	Pharmacia & Upjohn Spa	Polymeric derivatives of camptothecin
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
DE69927790T2 (de)	1998-02-25	2006-07-20	Sloan-Kettering Institute For Cancer Research	Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
ATE459616T1 (de)	1998-08-11	2010-03-15	Novartis Ag	Isochinoline derivate mit angiogenesis-hemmender wirkung
NZ511722A (en)	1998-11-20	2004-05-28	Kosan Biosciences Inc	Recombinant methods and materials for producing epothilone and epothilone derivatives
AU2001231143A1 (en)	2000-01-27	2001-08-07	Cytovia, Inc.	Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
PE20020354A1 (es)	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2003039529A1 (fr)	2001-11-07	2003-05-15	4Sc A.G.	Agents antibacteriens selectifs
WO2003055477A1 (fr)	2001-12-21	2003-07-10	7Tm Pharma A/S	Methode de traitement de troubles lies au recepteur de la melanocortine (mc), faisant intervenir un chelate et/ou un chelateur
GB0215676D0 (en) *	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
SI1569907T1 (sl)	2002-12-13	2016-06-30	Ym Biosciences Australia Pty Ltd	Na nikotinamidu osnovani kinazni inhibitorji
TW200505902A (en)	2003-03-20	2005-02-16	Schering Corp	Cannabinoid receptor ligands
US20070054916A1 (en)	2004-10-01	2007-03-08	Amgen Inc.	Aryl nitrogen-containing bicyclic compounds and methods of use
US20080167347A1 (en)	2005-01-20	2008-07-10	Shiongi & Co., Ltd.	Ctgf Expression Inhibitor
WO2006120178A1 (fr)	2005-05-11	2006-11-16	Novo Nordisk A/S	Nouveaux composes d'haloalkylsulfone substitues utiles dans le traitement de l'obesite et de diabetes
WO2007002441A1 (fr)	2005-06-24	2007-01-04	Emory University	Procedes d'utilisation d'inhibiteurs de tyrosine kinase competitive non atp afin de traiter des infections pathogenes
DE602005018911D1 (de)	2005-07-20	2010-03-04	Aventis Pharma Sa	1,4-Dihydropyridine-kondensierte Heterocyclen Verfahren zu deren Herstellung sowie Verwendung und Zusammensetzungen dergleichen
EP2606890A1 (fr) *	2006-04-05	2013-06-26	Novartis AG	Combinaisons d'inhibiteurs de BCR-ABL/C-KIT/PDGF-R TK pour traiter le cancer
WO2008021725A2 (fr)	2006-08-11	2008-02-21	Smithkline Beecham Corporation	Composés chimiques
EA200900573A1 (ru)	2006-10-20	2009-10-30	АйАрЭм ЭлЭлСи	Композиции и способы для модуляции рецепторов c-kit и pdgfr
US7939690B2 (en) *	2006-11-15	2011-05-10	High Point Pharmaceuticals, Llc	Haloalkylsulfone substituted compounds useful for treating obesity and diabetes
ATE548364T1 (de) *	2007-01-05	2012-03-15	Bristol Myers Squibb Co	Aminopyrazolkinasehemmer
WO2008112695A2 (fr)	2007-03-12	2008-09-18	Irm Llc	Inhibiteurs de protéine kinase et procédés d'utilisation de ceux-ci
WO2008124393A1 (fr)	2007-04-04	2008-10-16	Irm Llc	Derives de benzothiazole et leur utilisation en tant qu'inhibiteurs des proteines kinases
WO2008144253A1 (fr)	2007-05-14	2008-11-27	Irm Llc	Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci
CA2695071A1 (fr)	2007-08-02	2009-02-05	F. Hoffmann-La Roche Ag	Utilisation de derives de benzamide pour le traitement de troubles du snc
MY162760A (en)	2007-09-17	2017-07-14	Abbvie Bahamas Ltd	Anti-infective agents and uses thereof
EP2297097A2 (fr)	2008-06-11	2011-03-23	Irm Llc	Composés et compositions utiles pour le traitement de la malaria
AR073700A1 (es)	2008-09-29	2010-11-24	Boehringer Ingelheim Int	Heterociclos y composiciones farmaceuticas para usarse en el tratamiento de cancer, infecciones y enfermedades autoinmunitarias
WO2011008788A1 (fr)	2009-07-14	2011-01-20	Dawei Zhang	Composés à substitution fluoro en tant qu'inhibiteurs de kinase et leurs méthodes d'utilisation
JP2011057661A (ja)	2009-08-14	2011-03-24	Bayer Cropscience Ag	殺虫性カルボキサミド類
MX2012005332A (es)	2009-11-13	2012-10-15	Oscotec Inc	Inhibidores de cinasa.
JO3634B1 (ar) *	2009-11-17	2020-08-27	Novartis Ag	طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011082400A2 (fr)	2010-01-04	2011-07-07	President And Fellows Of Harvard College	Modulateurs du récepteur immunosuppresseur pd-1 et procédés d'utilisation de ceux-ci
CN102725296B (zh)	2010-01-29	2015-04-01	韩美科学株式会社	对蛋白激酶有抑制活性的噻吩并[3,2-d]嘧啶衍生物
WO2012129562A2 (fr)	2011-03-24	2012-09-27	The Scripps Research Institute	Composés et procédés pour l'induction de la chondrogenèse
CN102276500A (zh) *	2011-05-05	2011-12-14	西安交通大学	水杨酰胺类抗肿瘤化合物及其合成方法和用途
JP6007417B2 (ja)	2011-05-31	2016-10-12	レセプトスエルエルシー	新規ｇｌｐ−１受容体安定剤および調節剤
PT2861579T (pt) *	2012-05-15	2018-04-27	Novartis Ag	Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
KR20150008406A (ko)	2012-05-15	2015-01-22	노파르티스 아게	Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
WO2013171641A1 (fr)	2012-05-15	2013-11-21	Novartis Ag	Composés et compositions pour l'inhibition de l'activité abl1, abl2 et bcr-abl1
ES2670667T3 (es) *	2012-05-15	2018-05-31	Novartis Ag	Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1

2013
- 2013-05-09 PT PT137306528T patent/PT2861579T/pt unknown
- 2013-05-09 DK DK13730652.8T patent/DK2861579T5/da active
- 2013-05-09 PE PE2020000185A patent/PE20210667A1/es unknown
- 2013-05-09 KR KR1020147031773A patent/KR102091893B1/ko active Active
- 2013-05-09 HU HUE13730652A patent/HUE039138T2/hu unknown
- 2013-05-09 PL PL13730652T patent/PL2861579T3/pl unknown
- 2013-05-09 SI SI201330997T patent/SI2861579T1/en unknown
- 2013-05-09 MX MX2014013374A patent/MX359014B/es active IP Right Grant
- 2013-05-09 EP EP13730652.8A patent/EP2861579B9/fr active Active
- 2013-05-09 PE PE2014002006A patent/PE20150669A1/es not_active Application Discontinuation
- 2013-05-09 ME MEP-2018-117A patent/ME03095B/fr unknown
- 2013-05-09 NZ NZ701626A patent/NZ701626A/en unknown
- 2013-05-09 ES ES13730652.8T patent/ES2670601T3/es active Active
- 2013-05-09 TR TR2018/07023T patent/TR201807023T4/tr unknown
- 2013-05-09 CU CUP2014000131A patent/CU24265B1/es unknown
- 2013-05-09 BR BR112014026383-3A patent/BR112014026383B1/pt active IP Right Grant
- 2013-05-09 PE PE2016001014A patent/PE20161416A1/es unknown
- 2013-05-09 GE GEAP201313621A patent/GEP201606532B/en unknown
- 2013-05-09 MY MYPI2014703394A patent/MY169377A/en unknown
- 2013-05-09 HR HRP20180695TT patent/HRP20180695T1/hr unknown
- 2013-05-09 AU AU2013261127A patent/AU2013261127B2/en active Active
- 2013-05-09 AP AP2014007992A patent/AP3613A/xx active
- 2013-05-09 MA MA37519A patent/MA37519B1/fr unknown
- 2013-05-09 CA CA2868958A patent/CA2868958C/fr active Active
- 2013-05-09 SG SG11201407152XA patent/SG11201407152XA/en unknown
- 2013-05-09 JP JP2015512169A patent/JP6078639B2/ja active Active
- 2013-05-09 EA EA201491824A patent/EA024391B1/ru not_active IP Right Cessation
- 2013-05-09 WO PCT/IB2013/053768 patent/WO2013171639A1/fr not_active Ceased
- 2013-05-09 CN CN201380025539.6A patent/CN104302638B/zh active Active
- 2013-05-09 LT LTEP13730652.8T patent/LT2861579T/lt unknown
- 2013-05-09 RS RS20180497A patent/RS57177B1/sr unknown
- 2013-05-13 US US13/892,769 patent/US8829195B2/en active Active
- 2013-05-15 JO JOP/2013/0150A patent/JO3453B1/ar active
- 2013-05-15 TW TW102117263A patent/TWI560183B/zh active
- 2013-05-15 UY UY0001034811A patent/UY34811A/es active IP Right Grant
- 2013-05-15 AR ARP130101692A patent/AR091063A1/es active IP Right Grant
- 2013-09-05 UA UAA201412051A patent/UA113208C2/uk unknown
2014
- 2014-07-31 US US14/448,363 patent/US20140343086A1/en not_active Abandoned
- 2014-09-29 ZA ZA2014/07065A patent/ZA201407065B/en unknown
- 2014-10-13 TN TN2014000427A patent/TN2014000427A1/fr unknown
- 2014-10-14 CL CL2014002757A patent/CL2014002757A1/es unknown
- 2014-11-06 IL IL235566A patent/IL235566A/en active IP Right Grant
- 2014-11-12 DO DO2014000256A patent/DOP2014000256A/es unknown
- 2014-11-13 PH PH12014502531A patent/PH12014502531B1/en unknown
- 2014-11-14 SV SV2014004850A patent/SV2014004850A/es unknown
- 2014-11-14 GT GT201400253A patent/GT201400253A/es unknown
- 2014-11-14 CR CR20140519A patent/CR20140519A/es unknown
- 2014-11-14 CO CO14252517A patent/CO7131380A2/es unknown
2018
- 2018-05-18 CY CY20181100518T patent/CY1120235T1/el unknown
2022
- 2022-10-20 FR FR22C1053C patent/FR22C1053I2/fr active Active
- 2022-10-25 HU HUS2200046C patent/HUS2200046I1/hu unknown
- 2022-10-25 NO NO2022043C patent/NO2022043I1/no unknown
- 2022-10-26 NL NL301201C patent/NL301201I2/nl unknown
- 2022-11-02 CY CY2022033C patent/CY2022033I1/el unknown
- 2022-11-10 LT LTPA2022523C patent/LTC2861579I2/lt unknown
- 2022-12-02 LU LU00287C patent/LUC00287I2/en unknown

Also Published As

Publication number	Publication date
PH12014502531A1 (en)	2015-01-12
HRP20180695T1 (hr)	2018-06-01
TN2014000427A1 (en)	2016-03-30
NO2022043I1 (en)	2022-10-25
CN104302638B (zh)	2016-08-24
DOP2014000256A (es)	2015-02-27
MA37519B1 (fr)	2017-03-31
AR091063A1 (es)	2014-12-30
LT2861579T (lt)	2018-05-10
JP6078639B2 (ja)	2017-02-08
HUE039138T2 (hu)	2018-12-28
KR20150020170A (ko)	2015-02-25
LTC2861579I2 (fr)	2024-08-26
FR22C1053I2 (fr)	2023-11-10
DK2861579T5 (da)	2022-10-24
EA201491824A1 (ru)	2015-02-27
SV2014004850A (es)	2018-04-04
NL301201I2 (nl)	2022-12-07
CA2868958C (fr)	2020-09-01
CY2022033I2 (el)	2023-01-05
EP2861579B1 (fr)	2018-02-21
MA37519A1 (fr)	2016-06-30
ME03095B (fr)	2019-01-20
AU2013261127A1 (en)	2014-11-20
NZ701626A (en)	2016-02-26
IL235566A (en)	2016-09-29
US20130310395A1 (en)	2013-11-21
CU20140131A7 (es)	2015-04-29
PE20150669A1 (es)	2015-05-17
US20140343086A1 (en)	2014-11-20
PL2861579T3 (pl)	2018-07-31
PH12014502531B1 (en)	2015-01-12
BR112014026383A2 (pt)	2017-06-27
PE20210667A1 (es)	2021-04-05
LUC00287I2 (fr)	2025-05-12
GEP201606532B (en)	2016-08-25
KR102091893B1 (ko)	2020-03-23
CY1120235T1 (el)	2019-07-10
CR20140519A (es)	2015-03-26
WO2013171639A1 (fr)	2013-11-21
JP2015521185A (ja)	2015-07-27
CO7131380A2 (es)	2014-12-01
US8829195B2 (en)	2014-09-09
ZA201407065B (en)	2016-08-31
PE20161416A1 (es)	2017-01-08
HUS2200046I1 (hu)	2022-11-28
CU24265B1 (es)	2017-07-04
ES2670601T3 (es)	2018-05-31
BR112014026383B1 (pt)	2020-11-17
DK2861579T3 (en)	2018-05-28
MY169377A (en)	2019-03-26
CY2022033I1 (el)	2023-01-05
MX2014013374A (es)	2015-01-16
SI2861579T1 (en)	2018-05-31
FR22C1053I1 (fr)	2022-12-16
AU2013261127B2 (en)	2015-03-12
TW201400471A (zh)	2014-01-01
TWI560183B (en)	2016-12-01
EP2861579A1 (fr)	2015-04-22
AP3613A (en)	2016-02-29
GT201400253A (es)	2017-09-28
CL2014002757A1 (es)	2015-01-23
LTPA2022523I1 (fr)	2022-12-12
EA024391B1 (ru)	2016-09-30
RS57177B1 (sr)	2018-07-31
CN104302638A (zh)	2015-01-21
MX359014B (es)	2018-09-12
IL235566A0 (en)	2015-02-01
JO3453B1 (ar)	2020-07-05
EP2861579B9 (fr)	2018-08-29
UA113208C2 (xx)	2016-12-26
PT2861579T (pt)	2018-04-27
AP2014007992A0 (en)	2014-10-31
ES2670601T9 (es)	2022-11-30
CA2868958A1 (fr)	2013-11-21
HK1203495A1 (en)	2015-10-30
UY34811A (es)	2013-12-31
SG11201407152XA (en)	2014-11-27

Publication	Publication Date	Title
TR201807023T4 (tr)	2018-06-21	Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri.
EP2858988B1 (fr)	2018-02-28	Dérivés de benzamide pour inhiber l'activité d'abl1, d'abl2 et de bcr-abl2
EP2900637B1 (fr)	2017-08-09	Dérivés d'amide de pyrimidine, pyridine et pyrazine substitués par thiazole ou imidazole et composés similaires en tant qu'inhibiteurs de abl1, abl2 et bcr-abl1 pour le traitement du cancer, d'infections virales specifiques et de maladies snc specifiques
EP2861576B1 (fr)	2018-01-10	Dérivés de benzamide pour inhiber l'activité d'abl1, d'abl2 et de bcr-abl2
HK1203495B (en)	2018-07-20	Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1